About
The Germans Trias Heart Institute (iCor) is an interdisciplinary team devoted to the fight against cardiovascular disease from all forefronts. Dr Antoni Bayés Genís is the head of iCor at Germans Trias i Pujol University Hospital (HUGTiP), and full professor of the Faculty of Medicine at Universitat Autònoma de Barcelona (UAB). Currently, the iCor team includes surgeons, doctors, nurses, administrative staff and full-time multidisciplinary researchers from the ICREC Group. It is divided into ICREC Research Lab (MyoCare Lab, ASAC and PMP-Heart), Heart Failure Clinical Research, Coronary Surgery Research, Arrhythmias and Electrophysiology, Acute Coronary Syndrome, Coronary Imaging, Hemodynamics and Interventional Cardiology.
The ICREC Group (Heart Failure and Cardiac Regeneration) opened its doors in January 2002 with the aim of developing innovative biotherapies for cardiovascular diseases. Its current research activity is performed at IGTP’s laboratories and is coordinated by Dr Carolina Gálvez-Montón and Dr Santiago Roura Ferrer. The research activity of the group is divided into the following areas:
- Basic and Translational Research, historically known as the ICREC group (Heart Failure and Cardiac Regeneration) and now termed MyoCare Lab, with more than 20 years of experience in the study and application of novel biotherapies against myocardial infarction, mainly based in cell therapy, cardiac tissue engineering, adipose graft transposition procedure and extracellular vesicles. Recently, the group has opened new research lines on cardiac organoids, non-invasive monitoring of stents, electrophysiology, new pharmacological treatments of heart failure and their associated mechanisms of action, immunotherapy of chimeric antigen receptors, and cardiometabolism.
- Clinical Trials Support Area (ASAC), which aims to improve cross-sectional support for clinical trials conducted in the area of study of cardiovascular diseases by iCor at HUGTiP.
- Heart Precision Medicine Platform (PMP heart), with the focus on optimizing the value of biomarkers that improve the diagnosis, prognosis, monitoring and therapeutic guidance of patients with heart failure.
Keywords: Heart failure, cardiovascular diseases, advanced therapies, biomarkers, biotherapies, cardiac regeneration, animal models.
_1686219856.jpg)
Group leader
- Antoni Bayés Genís
Antoni Bayés Genís
Antoni Bayés-Genís (IGTP) is the Clinical Director of the Heart Area at Germans Trias i Pujol University Hospital, holds a PhD in Medicine, and is Full Professor of Cardiology at the Autonomous University of Barcelona (UAB). He is also the Principal Investigator of the Heart Failure and Cardiac Regeneration Research Group (ICREC) at IGTP and a faculty member of the UAB Faculty of Medicine at the Can Ruti Campus.
He is a world-renowned reference in the field of cardiology. His research focuses on novel biomarkers and biotherapies for personalized and precision cardiology. He has led and contributed to numerous research projects, particularly in the development of new biomarkers to improve the diagnosis and prognosis of heart failure, the study of sudden cardiac death, as well as regenerative medicine and telemedicine. His research has also contributed to the understanding of the so-called Bayés syndrome.
One of the most significant milestones in his research career was the development of a pioneering therapy to repair heart tissue after myocardial infarction. Known as PeriCord, this therapy consists of attaching a bioimplant of stem cells directly to the patient's heart to regenerate the damaged area and improve cardiac function.
He has authored over 1,045 SCI-indexed scientific articles in high-impact international journals and has contributed to more than 600 national and international conferences, delivering oral presentations. He has been awarded 49 competitive research grants, generating over €8 million in research funding. He is a Full Professor of Medicine-Cardiology and has supervised and co-supervised 25 doctoral theses.
His innovative research has led to the development of multiple medical technologies and the registration of ten patents, two of which have been licensed to U.S. biotechnology companies. Another patent was awarded a "Llavor" project by the Government of Catalonia in 2020, supporting prototype development and the creation of a spin-off company. In 2022, he co-founded a startup, Nimble Diagnostics, in collaboration with the Germans Trias i Pujol Research Institute, the Polytechnic University of Catalonia, and the University of Barcelona (IGTP-UPC-UB), which subsequently secured €2.5 million from the EIC Accelerator program. He has also established several collaboration agreements with biotechnology companies. He currently serves as a Board member and President of the Heart Failure Association of the European Society of Cardiology (ESC).Contact: abayes.germanstrias(ELIMINAR)@gencat.cat
ORCID: 0000-0002-3044-197X
Team
Deputy directors, Established researchers
Santiago Roura Ferrer(ELIMINAR)
Carolina Gálvez Montón(ELIMINAR)
Established researchers
Carolina Soler Botija(ELIMINAR)
Paloma Gastelurrutia Soto(ELIMINAR)
Elena Revuelta López(ELIMINAR)
Oriol Rodriguez Leor(ELIMINAR)
Felipe Bisbal Van Bylen(ELIMINAR)
Mar Domingo Teixidó(ELIMINAR)
Cosme Garcia Garcia(ELIMINAR)
Victoria Delgado García(ELIMINAR)
Recognised researchers
Gemma Ferrer Curriu(ELIMINAR)
Oriol Iborra Egea(ELIMINAR)
Leonie Schoch(ELIMINAR)
Esther Jorge Vizuete(ELIMINAR)
Albert Teis Soley(ELIMINAR)
Evelyn Santigo Vacas (ELIMINAR)
Postdoctoral fellow
Yara Onetti(ELIMINAR)
First stage researchers
Yvan Courageux (ELIMINAR)
Daina Martínez Falguera(ELIMINAR)
Georgina Iraola Picornell(ELIMINAR)
Maria Kalil Filló(ELIMINAR)
Support
Sheila Crespo Castillo(ELIMINAR)
Technicians
Borja Montejo Collet(ELIMINAR)
Francesc Poblador Bonet(ELIMINAR)
Research nurse
Elena Barceló Cormano(ELIMINAR)
Beatriz Valencia Aguilar(ELIMINAR)
Research lines
The group has primarily focused on two main areas: regenerative medicine, where it has developed and tested experimental models in vitro and in vivo, and has even been a pioneer in early human studies (adiFLAP trial: NCT01473433, AGTP II trial: NCT02798276, and the PERISCOPE study: NCT03798353); and precision medicine based on biomarkers. In this second area, ICREC has worked to understand and validate the use of circulating biomarkers in clinical settings. The group has one research line dedicated to each of these areas. In addition to these two historically most relevant lines, in recent years the group has launched new lines of work based on the incorporation of new expert staff in other areas of knowledge, as well as collaborations with other research groups.
Extracellular vesicles
Researchers: Santiago Roura Ferrer, Yvan Courageux, Leonie Schoch
The group is developing a novel biological medicinal product, EVCord, based on extracellular vesicles derived from mesenchymal cells from Wharton's jelly of the umbilical cord, for the treatment of the acute inflammatory response following myocardial infarction. In parallel, the integration of high-resolution nuclear magnetic resonance spectroscopy into the design of bioprocesses for the manufacture of clinical-grade extracellular vesicles is being explored.
Translational preclinical research
Researchers: Carolina Gálvez Montón, Carolina Soler Botija, Daina Martínez Falguera, Georgina Iraola Picornell, Esther Jorge Vizuete, Maria Kalil Filló, Oriol Rodriguez Leor, Felipe Bisbal Van Bylen, Victoria Delgado García, Yara Onetti
Experimental work in preclinical models is a well-established research line, with proven expertise in models of myocardial infarction, heart failure and hypertensive cardiomyopathy. Several cardiac tissue engineering projects have been developed using decellularised natural tissues, resulting in more than 17 publications in high-impact scientific journals.
One of the main current projects at ICREC is to help assess the effect of cardiac organoids (COs) for cell therapy in a preclinical model of myocardial infarction. In collaboration with Dr Pfannkuche (University of Cologne) and Dr Bastiaan Boukens (Maastricht University), COs may emerge as a potential treatment for myocardial infarction.
In addition, the group is working on the development of decellularised and re-endothelialised human vascular grafts within the VASCRAFT project, in collaboration with Dr Cristina Castells (Banc de Sang i Teixits de Barcelona) and Dr Jordi Martorell (Institut Químic de Sarrià). The main objective is to create an advanced therapy medicinal product as a vascular substitute for arterial bypass surgery.
Other research lines include the study of new drugs for myocardial infarction, as well as collaborations for the development of new implantable stents and vascular monitoring devices.
Cardiometabolism
Researchers: Gemma Ferrer Curriu, Cosme García García
Technician: Francesc Poblador
The cardiometabolism line was established in 2021 with three main objectives: to investigate cardiac remodelling in heart failure in order to identify new therapeutic targets; to study whether modulation of cardiac remodelling may help protect against the progression of heart failure; and to uncover the mechanisms of action of cardioprotective drugs.
A key line of work focuses on the study of new drugs to assess potential cardiovascular effects in models of heart failure with preserved ejection fraction.
Heart Precision Medicine Platform (PMP-Heart)
Researcher: Elena Revuelta López
Technician: Borja Montejo
Current work focuses both on the study of known biomarkers and the discovery of new biomarkers to improve the management of cardiac disease. To this end, the group has access to extensive collections of plasma and serum samples from patients treated in the Cardiology Department and collaborates with other hospitals, both nationally and internationally, to achieve robust and internationally relevant results.
Clinical Trials Support Area / Clinical Trials Unit - ASAC
Coordinators: Paloma Gastelurrutia Soto, Mar Domingo, Mª Elena Barceló Cormano, Beatriz Valencia Aguilar
Since 2018, ASAC has coordinated and supported both clinical studies carried out in the Cardiology Department of HUGTiP (Haemodynamics, Arrhythmias, Heart Failure, Cardiac Imaging, Coronary Unit and Clinical Care Unit), as well as two translational trials derived from basic and preclinical research in advanced therapies where ICREC acts as sponsor:
- AGTP II (NCT02798276), a multicentre (11 centres), prospective and randomised study to evaluate the efficacy of a novel surgical procedure based on the transposition of an adipose graft in patients with non-revascularisable myocardial infarction.
- PERISCOPE trial (NCT03798353), a clinical study entitled "Pericardial matrix with mesenchymal stem cells for the treatment of patients with infarcted myocardial tissue".
Innovation and technology transfer
Lead: Oriol Iborra Egea
This line was established in 2018 with the aim of protecting industrial and intellectual property, valorising research results and, where appropriate, exploiting and transferring the knowledge generated at ICREC to the productive sector.
Oriol Iborra, a researcher within the ICREC group, supports and advises researchers from ICREC and iCor with ideas or results that may have transfer potential. The unit may also be responsible for directly managing the development and transfer of these results through knowledge and product licensing or the creation of spin-offs.
Active projects
Organoids cardíacs humans per a l'infart de miocardi crònic: reparació i regeneració cardíaca
PI: Carolina Gálvez Montón
Funding agency: Societat Catalana de Cardiologia
Agency code: Beques SCC2025-11.25
Duration: 26/05/2025 a 25/05/2026
CIBERCV
PI: Antoni Bayes Genis
Co-PI: Carolina Gálvez Montón
Funding agency: CIBER Enfermedades Cardiovasculares
Agency code: CB16/11/00403
Start date: 2017
Avaluació dels efectes protectors antiarítmics i antiinflamatoris de l'empagliflozina en un model pre-clínic porcí d'infart de miocardi
PI: Carolina Gálvez Montón, Felipe Bisbal Van Bylen
Funding agency: Hospital Universitari Germans Trias i Pujol (Llegat JMC)
Agency code: 2022_42
Duration: 01/09/2023 – 31/08/2026
GALVANO: Optimización, Validación y Explotación de una Plataforma de Producción versátil de Vesículas Extracelulares Grado Clínico mediante Tecnología Analítica de Proceso
PI: Santiago Roura
Funding agency: Ministerio de Ciencia, Innovación y Universidades
Agency code: CPP2023-010430
Duration: 01/12/2024 – 30/11/2027
Coronary stent monitoring using a new noninvasive nonionizing microwave interferometry technique
PI: Oriol Rodríguez
Funding agency: Ministerio de Ciencia, Innovación y Universidades
Agency code: CPP2023-010880
Duration: 01/03/2024 – 28/02/2027
Inmunoterapia para la fibrosis miocárdica con anticuerpos específicos anti-FAP (Proteína de Activación de Fibroblastos)
PI: Antoni Bayés
Funding agency: Sociedad Española de Cardiología
Agency code: SEC/FEC-INV-BAS 24/10
Duration: 24/10/2024 – 31/12/2028
Estudio del papel de la proteína Oncostatina M en la fase aguda post-infarto
PI: Fernando Rueda
Funding agency: Sociedad Española de Cardiología
Agency code: SEC/FEC-INV-BAS 24/02
Duration: 24/10/2024 - 31/12/2028
CERTERA
PI: Carolina Gálvez Montón
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: CERT0052
Duration: 03/12/2024 a 30/06/2026
Mecanismo de acción de Survodutida en el corazón en un modelo de ratón obeso/hipertenso
IP: Antoni Bayés Genís
Funding agency: Boehringer Ingelheim España
Duration: 01/10/2025 - 31/10/2026
Evaluación multiparamétrica de la congestión en pacientes con insuficiencia cardiaca: precisión pronóstica de la congestión vascular por ecografía y correlación con biomarcadores cardiacos
PI: Mar Domingo Teixidor
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI22/01751
Duration: 01/01/2023 – 31/12/2025 (extended until 30/09/2026)
Organoides cardíacos para terapia celular en un modelo preclínico de infarto de miocardio
PI: Antoni Bayés Genís
Funding agency: Ministerio de Ciencia e Innovación
Agency code: PID2022-142219OB-I00
Duration: 01/09/2023 – 01/09/2026
Vesícules extracel·lulars com a nova teràpia avançada contra el xoc cardiogènic: producció, validació i primera aplicació clínica en humans SHOCK-MI-EV
PI: Santiago Roura Ferrer, Antoni Bayes Genís
Funding agency: Hospital Universitari Germans Trias i Pujol (Llegat JMC)
Agency code: 2021_44
Duration: 01/09/2023 – 31/08/2026
BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure (BIOTOOL-CHF)
PI: Antoni Bayés Genís
Funding agency: European Commission
Agency code: 101095653
Duration: 01/10/2023 – 30/09/2028
Past projects
In vitro method for predicting mortality risk in patients suffering from cardiogenic shock
PI: Ferran Rueda Sobella
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: DTS22/00180
Duration: 01/01/2023 - 31/12/2024 (extended to 31/12/2025)
Base genética y biológica de la cardiopatía inducida por marcapaso
PI: Víctor Bazán Gelizo
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI21/01700
Duration: 01/01/2022 - 31/12/2024 (extended to 30/06/2025)
Red RICORS en Terapias Avanzadas (TERAV)
PI: Antoni Bayés Genís
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: RD21/0017/0022
Duration: 2022 - 2025
Inflammatory modulation of STEMI-derived cardiogenic shock with extracellular vesicles (EVs): EV4MI Trial
PI: Cosme García-García, Santiago Roura Ferrer
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: ICI20/00135
Duration: 01/01/2021 - 31/12/2024 (extended to 31/12/2025)
Nuevo injerto humano vascular descelularizado y re-endotelizado producido mediante ingeniería de tejidos para su uso en derivación arterial (VasCraft)
PI: Christian Muñoz Guijosa
Funding agency: Ministerio de Ciencia e Innovación
Agency code: CPP2021-008438
Duration: 01/07/2022 - 30/06/2025 (extended until 31/12/2025)
Somatic mutations and clonal hematopoiesis as predictors and drivers of heart failure progression (Myoclonal)
PI: Antoni Bayés Genís
Funding agency: Fundació "la Caixa"
Agency code: HR22-00732
Duration: 01/10/2022 - 30/09/2025
Estudio del impacto del tratamiento con inhibidores de SGLT2 en el estrés oxidativo y la fibrosis cardíaca en pacientes con insuficiencia cardíaca
PI: María Ruiz Cueto
Funding agency: Programa Trias Talents Facultatius HUGTiP 2021
Duration: 2022 - 2023
Avaluació dels efectes protectors antiarítmics i antiinflamatoris de l'empagliflozina en un model porcí d'infart de miocardi
PI: Júlia Aranyó Llach
Funding agency: Programa Trias Talents Facultatius HUGTiP 2021
Duration: 2022 - 2023
Efecto de los fármacos inhibidores de los receptores de angiotensina II y neprisilina sobre la presión arterial pulmonar en pacientes con insuficiencia cardiaca y fracción de eyección preservada monitorizados con el dispositivo CARDIOMEMS
PI: Pau Codina Verdaguer
Funding agency: Programa Trias Talents Facultatius HUGTiP 2021
Duration: 2022 - 2023
In vitro method for predicting mortality risk in patients suffering from cardiogenic shock (CS4P)
PI: Antoni Bayés Genís
Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
Duration: 2022 - 2023
Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue (PERISCOPE)
PI: Josep Lupón Rosés
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: ICI19/00039
Duration: 01/01/2020 - 31/12/2024
Bioimplantes cardíacos de nueva generación basados en vesículas extracelulares para infarto de miocardio: correcta fabricación y estudio pre-clínico. Acrónimo: EV4MI (extracellular vesicle for myocardial infarction) study
PI: Santiago Roura Ferrer
Funding agency: Ministerio de Ciencia e Innovación
Agency code: PID2019-110137RB-I00
Duration: 01/06/2020 - 31/05/2024
Mètode in vitro per predir el risc de mortalitat en pacients que pateixen xoc cardiogènic
PI: Antoni Bayés Genís
Funding agency: AGAUR (Ajuts per a projectes de valorització i transferència de coneixement desenvolupats per innovadors en estades en entitats del sistema de recerca i innovació de Catalunya (Innovadors) per a l'any 2021)
Agency code: 2021 INNOV 00023
Duration: 01/11/2022 - 30/06/2024
Effect of Empagliflozin on biventricular remodeling and performance in an experimental large - animal model of postcapillary pulmonary hypertension
PI: Antoni Bayés-Genís, Carolina Gálvez Montón, Evelyn Santiago Vacas
Funding agency: Boehringer Ingelheim España, S.A.
Duration: 2024 - 2025
Ajuts per donar suport a l'activitat científica dels grups de recerca de Catalunya (SGR-Cat 2021)
PI: Antoni Bayés Genís
Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
Agency code: 2021 SGR 01437
Duration: 2021 - 2023 - extended to 30 June 2025
Estudio prospectivo, aleatorizado, multicéntrico, abierto, para evaluar la no inferioridad de una estrategia personalizada de precisión para la prevención de la muerte súbita en pacientes con miocardiopatía dilatada no isquémica (Estudio CIBER-Spanish I)
PI: Antoni Bayés Genís
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PMP21/00064
Duration: 16/12/2021 - 31/12/2025
Incorporació de personal de suport als grups de recerca
PI: Antoni Bayés Genís
Funding agency: Departament de Salut (PERIS)
Agency code: SLT028/23/000249
Duration: 01/07/2023 - 31/12/2025
Utilidad de Sacubitrilo/ValsartaN y Empagliflozina en la prevención de Arritmias ventriculares en la carDiopatía isquémica: de la ómica al mapeo miocárdico invasivo
PI: Carolina Gálvez Montón, Felipe Bisbal Van Bylen
Funding agency: Ministerio de Ciencia e Innovación
Agency code: PID2021-124703OB-I00
Duration: 01/09/2022 - 31/08/2025
Validación analítica y clínica del primer immunoensayo para personalizar estrategias terapéuticas en pacientes con shock cardiogénico
PI: Elena Revuelta López
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI21/01703
Duration: 01/01/2022 - 31/12/2025
Elucidating the potential interaction of empagliflozin with NHE1: structural and biochemical analysis
PI: Antoni Bayes-Genís, Oriol Iborra Egea
Funding agency: Boehringer Ingelheim España, S.A.
Duration: 2022 - 2023
Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue (PERISCOPE)
PI: Antoni Bayés Genís
Funding agency: Ministerio de Ciencia e Innovación
Duration : 2018 - 2021
Caracterització Multimodal del Substrat Arrítmic resultant de la Teràpia de Regeneració Cardíaca (AGTP) en un Model de Infart de Miocardi Crònic
PI: Raquel Adeliño Recasens
Funding agency: European Social Funds
Agency code: 2020 FI_B 00637
Duration: 01/11/2020 - 31/11/2023
In vitro method for predicting mortality risk in patients suffering from cardiogenic shock (CS4P)
Agency code: 2021 PROD 00052
Duration: 19/10/2022 - 18/07/2024
In vitro method for predicting mortality risk in patients suffering from cardiogenic shock (CS4P)
PI: Antoni Bayés Genís
Funding agency: Fundació "la Caixa" (Caixaimpulse Validate)
Agency code: CI21-00283
Duration: 16/06/2021 - 24/06/2024
Efficacy of the Adipose Graft Transposition Procedure (AGTP) in patients with a myocardial scar: The AGTP II trial
PI: Antoni Bayes-Genís
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PIC18/00014
Duration: 01/01/2019 - 31/12/2024
Mutaciones somáticas y hematopoyesis clonal como factores de riesgo en aterosclerosis: del laboratorio a la clínica (Atheroclonal)
PI: Antoni Bayés Genís (WP)
Funding agency: Ministerio de Ciencia e Innovación
Agency code: PLEC2021-008194
Duration: 01/01/2022 - 31/12/2024
Area of cardiovascular disease research sponsor
Scientific publications
Highlighted publications
Bisbal F, Aranyó J, Iraola-Picornell G, Sanchez-Quintana D, Martínez-Falguera D, Sarrias A, Fadeuilhe E, Bazan V, Teis A, Rodríguez-Leor O, Villuendas R, Curiel C, Armengol MP, Pey I, Roura S, Bayés-Genís A, Gálvez-Montón C. Anatomy of the Isthmus: Unraveling the Tissue Composition of the Ventricular Tachycardia Diastolic Pathway. JACC Clin Electrophysiol. 2026 Apr;12(4):667-680. DOI: 10.1016/j.jacep.2025.10.014.
Vilalta V, Delgado V. TAVI for native aortic regurgitation. Lancet. 2025 Dec 13;406(10521):2728-2729. DOI: 10.1016/S0140-6736(25)02273-1.
Martínez-Falguera D, Aranyó J, Ferrer-Curriu G, Teis A, Revuelta-Lopez E, Diaz-Güemes I, Monguió-Tortajada M, Fadeuilhe E, Rodríguez-Leor O, Poblador F, Montejo B, Roura S, Villuendas R, Sarrias A, Bazan V, Jorge E, Delgado V, Jimenez-Trinidad FR, Rigol M, Martinez-Micaelo N, Amigó N, Bayes-Genis A, Bisbal F, Gálvez-Montón C. Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study. J Am Heart Assoc. 2025 Jun 3;14(11):e040214. DOI: 10.1161/JAHA.124.040214.
Bayes-Genis A. Pushing boundaries: the uncharted territory of managing a 110-year-old patient. Eur Heart J. 2025 May 2;46(17):1577-1578. DOI: 10.1093/eurheartj/ehaf030.
Revuelta-López E, de la Espriella R, Miñana G, Santas E, Villar S, Sanchis J, Bayés-Genís A, Núñez J. The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden. Sci Rep. 2025 Jan 14;15(1):1905. DOI: 10.1038/s41598-024-84622-7.
Additional information
Collaborative networks
The Heart Institute (iCor) is an active member of the CIBER de Enfermedades Cardiovasculares (CIBERCV), a national collaborative research network funded by the Instituto de Salud Carlos III. The main objective of CIBERCV is to promote excellence in cardiovascular research through coordinated, multidisciplinary collaboration among leading Spanish research groups, with a strong emphasis on translational research, innovation, and the rapid transfer of scientific knowledge into clinical practice. More information
Doctoral theses
Title: Dipòsits d'amiloide auricular i estenosi aòrtica: implicacions clíniques i pronòstiques en la cirurgia de substitució valvular aòrtica
Author: Ignasi Julià Amill
Supervisor: Elena Revuelta
University: Universitat Autònoma de Barcelona
Date of defence: 19/12/2025
Title: Calculadores de risc en insuficiència cardíaca
Author: Pau Codina
Supervisor: Antoni Bayés; Elisabet Zamora
University: Universitat Autònoma de Barcelona
Date of defence: June 2025
Title: Impact of new pharmacological strategies for the treatment of acute myocardial infarction: study of the effects and synergy of sacubitril/valsartan and empagliflozin.
Author: Daina Martínez Falguera
Supervisor: Antoni Bayés Genís
University: Universitat de Barcelona
Date of defence: 23/04/2025
Title: Métodos de valoración del estado nutricional: utilidad en el pronostico clínico de pacientes con insuficiencia cardíaca crónica
Author: Clara Joaquín Ortiz
Supervisors: Núria Alonso Pedrol, Josep Lupón Rosés, Manel Puig Domingo
University: Universitat Autònoma de Barcelona
Date of defence: 24/02/2023
Title: Terapias mínimamente invasivas para el tratamiento de la estenosis aórtica. Bioprótesis sin sutura y prótesis valvular aórtica transcateter
Author: Victoria Vilalta del Olmo
Supervisors: Antoni Bayés Genís, Josep Rodés Cabau
University: Universitat Autònoma de Barcelona
Date of defence: 01/03/2023
Title: La insuficiència cardíaca com a complicació de l'infart agut de miocardi. Anàlisi segons la forma de presentació i pronòstic a llarg termini
Author: Maria José Martínez Membrive
Supervisor: Cosme García; Antoni Bayés (Tutor)
University: Universitat Autònoma de Barcelona
Date of defence: 24/11/2025
Title: El Codi Infart com a xarxa d'atenció a l'infart amb elevació del ST: anàlisi dels diferents circuits i la seva implicació pronòstica. Anàlisi de l'impacte de la reperfusió amb angioplàstia primària en les complicacions de l'infart
Author: Oriol de Diego Soler
Supervisor: Cosme García; Josep Lupón (Tutor)
University: Universitat Autònoma de Barcelona
Date of defence: 02/03/2025
Title: Factores Asociados al impacto pronóstico de la Extracorporeal Membrane Oxygenation venoarterial en pacientes con shock cardiogénico refractario. Estudio de la microcirculación, flujo del ECMO y estrategias de ventilación
Author: Santiago Ramón Montero Aradas
Supervisors: Jesús Álvarez García, Matthieu Schmidt
University: Universitat Autònoma de Barcelona
Date of defence: 17/03/2023
Title: Evolució, pronòstic i factors predictors de fibril·lació ventricular primària a l'infart agut de miocardi amb elevació del segment ST
Author: Maria Teresa Oliveras Vilà
Supervisors: Antoni Bayés Genís, Cosme García García
University: Universitat Autònoma de Barcelona
Date of defence: 10/02/2023
Innovation
In 2025, significant progress was achieved by NIMBLE Diagnostics, a spin-off focused on non-invasive microwave-based technology for the detection of coronary in-stent restenosis. Notably, the first pilot clinical trial (NIMBLE-I) has been successfully initiated, marking a key milestone in the clinical translation of this innovative diagnostic approach. This study aims to evaluate the feasibility and accuracy of real-time, radiation-free stent monitoring in patients, representing a potential paradigm shift in the follow-up of coronary interventions. More information
Outreach
In 2025, the Heart Institute (iCor) strengthened its commitment to public engagement and science communication through the launch of a renewed institutional website (www.icor.cat) and an active presence on social media platforms, including Instagram, LinkedIn, and X (formerly Twitter). In collaboration with the communication teams of IGTP and HUGTiP, and with the support of a professional science communicator, iCor regularly disseminated research highlights, clinical advances, educational content, and institutional activities to both the scientific community and the general public. These initiatives aimed to improve cardiovascular health awareness, promote knowledge transfer, and increase the visibility of ongoing research and innovation activities. Content included updates on clinical trials, participation in international congresses, educational videos, and news on emerging therapies and technologies, contributing to a closer connection between research, healthcare professionals, and society.
News
Banc de Sang i Teixits hosts an Innomed meeting to share capabilities in advanced therapies
The Innomed community visited the Banc de Sang i Teixits (BST) yesterday as part of a new meeting organised within the framework of the Innomed programme, led by the Germans Trias i Pujol Research Institute (IGTP), with the aim of strengthening connections between research institutions, hospitals and organisations within the biomedical ecosystem, and exploring new opportunities for collaboration in the field of advanced therapies and health innovation.
IGTP and Germans Trias Hospital join forces on the podcast Un bri de ciència, launching a new episode on myocardial infarction
As part of the European Day for the Prevention of Cardiovascular Risk, the podcast launches its eleventh episode, dedicated to myocardial infarction, featuring Ferran Rueda and Santi Roura from Germans Trias i Pujol Hospital and Research Institute, respectively.
Contact
extn 6350
More links
iCor website · iCor news · Follow @IcorCat on X · Donate via Amics de Can Ruti